28
Participants
Start Date
March 31, 2002
Primary Completion Date
September 30, 2005
Study Completion Date
June 30, 2009
dendritic cell-MART-1 peptide vaccine
Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles
National Institutes of Health (NIH)
NIH
Jonsson Comprehensive Cancer Center
OTHER